Table 5.
Diabetic patients divided according to type of diabetes and diabetes as comorbid factor or kidney disease.
| Diabetic Patients | Type 1 | Type 2 | p | Type 2 CKD | Type 2 Comorb | p | Type 2 PtU ≥ 1 g | Type 2 PtU < 1 g | p |
|---|---|---|---|---|---|---|---|---|---|
| 149 | 12 | 137 | 42 | 95 | - | 70 | 67 | - | |
| Males (%) | 4 | 83 | 0.076 | 26 | 57 | 0.833 | 47 | 36 | 0.109 |
| (33.33%) | (60.58%) | (61.90%) | (60%) | (67.10%) | (53.70%) | ||||
| BMI | 23.24 | 27.39 | 0.014 | 27.97 | 27.18 | 0.17 | 27.55 | 26.99 | 0.84 |
| median (min–max) | (18.49–29.32) | (18.33–44.92) | (18.77–41.03) | (20.37–44.92) | (19.15–41.03) | (20.37–44.92) | |||
| IQR | 4.98 | 4.61 | 6.28 | 3.99 | 4.57 | 4.37 | |||
| Age | 43.5 | 71 | 0.031 | 66.5 | 72 | 0.181 | 68 | 73 | 0 |
| median (min–max) | (29–62) | (19–92) | (46–85) | (19–92) | (47–86) | (19–92) | |||
| IQR | 15.5 | 12 | 10 | 11 | 11 | 13 | |||
| Age over 65 (%) | 0 | 119 (86.86%) | - | 31 (73.81%) | 88 (92.63%) | 0.001 | 46 (65.70%) | 61 (91%) | 0 |
| Age over 80 (%) | 0 | 40 (29.20%) | - | 6 (14.28%) | 34 (35.79%) | 0.011 | 5 (7.1%) | 18 (26.90%) | 0.002 |
| Charlson | 4 | 9 | 0.06 | 8 | 9 | 0.032 | 8 | 9 | 0.035 |
| median (min–max) | (2–8) | (2–13) | (5–11) | (2–13) | (5–11) | (2–13) | |||
| IQR | 1.5 | 3 | 2 | 2 | 2 | 2 | |||
| Charlson ≥ 7 (%) | 2 (16.17%) | 120 (87.59%) | 0 | 33 (78.57%) | 87 (91.58%) | 0.033 | 58 (82.90%) | 62 (92.50%) | 0.071 |
| Charlson ≥ 10 (%) | 0 (0%) | 44 (32.12%) | 0.019 | 6 (14.29%) | 38 (40%) | 0.0002 | 14 (20.29%) | 30 (44.12%) | 0.003 |
| Cardiopathy (%) | 3 (25%) | 93 (67.88%) | 0.009 | 25 (59.52%) | 68 (71.58%) | 0.163 | 41 (58.60%) | 52 (77.60%) | 0.013 |
| SCreatinine | 2.45 | 2.8 | 0.393 | 2.6 | 2.9 | 0.858 | 2.89 | 2.7 | 0.695 |
| median (min–max) | (0.9–4.7) | (1–6.8) | (1–6.4) | (1.1–6.8) | (1–6.8) | (1.4–5) | |||
| mg/dL IQR | 1.95 | 1.4 | 1.5 | 1.4 | 1.6 | 2.4 | |||
| eGFR-EPI (mL/min) | 24.95 | 19.8 | 0.026 | 20.85 | 19.5 | 0.993 | 19.3 | 19.9 | 0.875 |
| median (min–max) | (12.10–79.70) | (6.3–75.5) | (6.3071.60) | (7.4–77.7) | (6.3–75.5) | (7.7–54.5) | |||
| IQR | 21.3 | 10.7 | 14.1 | 11.2 | 11.5 | 10.1 | |||
| GFR < 15 at start n (%) | 3 (25%) | 32 (23.36%) | 0.897 | 8 (19.05%) | 24 (25.26%) | 0.428 | 16 (22.90%) | 16 (23.90%) | 0.524 |
| GFR < 10 at start n (%) | 0 | 13 (9.49%) | 0.264 | 5 (11.90%) | 8 (8.42%) | 0.472 | 10 (14.30%) | 3 (4.5%) | 0.05 |
| PtU (g/day) | 3.05 | 1 | 0.041 | 3.25 | 0.5 | 0 | 3 | 0.25 | 0 |
| median (min–max) | (0.2–10.4) | (0.1–15.8) | (0.2–15.8) | (0.08–7) | (1–15.8) | (0.1–0.9) | |||
| IQR | 4.1 | 2.67 | 3.5 | 1.3 | 3.2 | 0.3 |
Legend: Charlson: Charlson’s comorbidity index; E-GFR EPI: GFR according to the CKD-EPI 587 equation; CKD: Chronic kidney disease; comorb: Comorbidity; PtU: Proteinuria; IQR: Interquartile range. Type 2: Five patients with steroid-induced diabetes are included.